Ally Bridge Group (ny) LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Ally Bridge Group (ny) LLC disclosed 23 US equity positions worth $77.6m in its Q2 2026 13F filing. The largest position was NERV at 15.6% of the reported book, followed by PROMIS NEUROSCIENCES INC and TRAX. Against the Q1 2026 filing, it opened 10 new positions, added to 2 and reduced 9 among the top 23 holdings.
What did Ally Bridge Group (ny) LLC own in Q2 2026? Top 23 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | NERV MINERVA NEUROSCIENCES INC | 15.6% | $12.1m | 2,175,802 | 31% | added | |
| 2 | PROMIS NEUROSCIENCES INC | 10.5% | $8.2m | 620,319 | 50% | added | |
| 3 | TRAX FIRST TRACKS BIOTHERAPEUTICS | 7.4% | $5.7m | 284,287 | – | new | |
| 4 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 5.2% | $4.0m | 16,493 | – | new |
| 5 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 5.0% | $3.8m | 140,000 | – | new |
| 6 | WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 4.8% | $3.7m | 817,939 | 0% | held |
| 7 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 4.4% | $3.4m | 83,300 | -48% | reduced |
| 8 | CLYM CLIMB BIO INC | Healthcare | 4.2% | $3.2m | 249,172 | – | new |
| 9 | KURA KURA ONCOLOGY INC | Healthcare | 4.1% | $3.2m | 290,000 | – | new |
| 10 | CTMX CYTOMX THERAPEUTICS INC. | Healthcare | 3.7% | $2.9m | 775,000 | -14% | reduced |
| 11 | AVTX AVALO THERAPEUTICS INC | Healthcare | 3.6% | $2.8m | 150,000 | – | new |
| 12 | PALI PALISADE BIO INC | Healthcare | 3.3% | $2.6m | 1,229,000 | – | new |
| 13 | SLDB SOLID BIOSCIENCES INC | Healthcare | 3.3% | $2.6m | 255,959 | -67% | reduced |
| 14 | ANTX AN2 THERAPEUTICS INC | 3.3% | $2.5m | 526,315 | 0% | held | |
| 15 | URGN UROGEN PHARMA LTD | Healthcare | 3.3% | $2.5m | 69,183 | -66% | reduced |
| 16 | CATX PERSPECTIVE THERAPEUTICS INC | 3.3% | $2.5m | 743,958 | -20% | reduced | |
| 17 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 3.2% | $2.5m | 67,500 | – | new |
| 18 | IVA INVENTIVA SA | 3.1% | $2.4m | 634,800 | -15% | reduced | |
| 19 | ALMS ALUMIS INC | Healthcare | 2.8% | $2.2m | 76,459 | -54% | reduced |
| 20 | OVID OVID THERAPEUTICS INC | Healthcare | 2.2% | $1.7m | 624,561 | -78% | reduced |
| 21 | EPRX EUPRAXIA PHARMACEUTICALS INC | 2.1% | $1.7m | 252,175 | -62% | reduced | |
| 22 | IBIO IBIO INC | 0.9% | $682.8k | 390,147 | – | new | |
| 23 | TRAW TRAWS PHARMA INC | 0.9% | $663.0k | 786,236 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.